Status:
COMPLETED
Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male and female subjects between ages of 18 to 60 in good health
- History of atopy for at least 2 years and positive skin prick test to ragweed allergen
- Exclusion criteria:
- History of asthma treated with corticosteroids
- Smokers with a smoking history of \> 10 pack/years or smoking in the past year
- History of chronic obstructive pulmonary disease
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00929968
Start Date
June 1 2009
Last Update
December 19 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
2
Novartis Investigative Site
Ottawa, Ontario, Canada